Crossmark

Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Published Online: 2021-07-16

Published Print: 2021-09

Authors

Deshotels, Matthew R.

Virani, Salim S.

Ballantyne, Christie M.
Funding

Funding for this research was provided by:

U.S. Department of Veterans Affairs
License Information

Text and Data Mining valid from 2021-07-16

Version of Record valid from 2021-07-16
More Information

Article History

Accepted: 28 March 2021

First Online: 16 July 2021

Declarations

:

: Matthew R. Deshotels declares no conflicts of interests.Salim S. Virani receives research support from the US Department of Veterans Affairs, World Heart Federation, and Tahir and Jooma Family and has received an honorarium from the American College of Cardiology (as an associate editor for Innovations ).Christie M. Ballantyne has received grant/research support to his institution from Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, National Institutes of Health, and American Heart Association and is a consultant for Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Corvidia, Esperion, Genentech, Gilead, Matinas BioPharma Inc., New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi-Synthelabo.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current